Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2016 Mar 4;298:9–18. doi: 10.1016/j.taap.2016.03.001

Table 1.

Summary of results for rolipram formulations that were tested in vivo.

Formulation1 In vitro release at 4 h Maximum inhibition of airway hyperreactivity Maximum inhibition of pulmonary edema
100% rolipram 70% 100% Not significant
40% rolipram/60% PLGA 36% 100% 48%
40% rolipram/55% PLGA/5% PEG 56% 100% Not significant
1

All generated by spray drying of methylene chlorine solutions using 0.4 mm nozzle; PLGA formulations contain 50:50 ratio of lactide:glycolide.